Adaptimmune Therapeutics plc
ADAP
$0.2504
-$0.0735-22.69%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 1,294.81% | 458.83% | 2,399.63% | -88.07% | -97.91% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1,294.81% | 458.83% | 2,399.63% | -88.07% | -97.91% |
| Cost of Revenue | 17.96% | -9.22% | 34.98% | 37.81% | -74.00% |
| Gross Profit | -9.01% | 121.65% | 453.46% | -233.90% | 71.74% |
| SG&A Expenses | 199.64% | 31.63% | -4.93% | 34.96% | -26.22% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 58.48% | 3.02% | 18.97% | 36.77% | 18.81% |
| Operating Income | -51.76% | 68.52% | 252.98% | -762.82% | -70.41% |
| Income Before Tax | -49.31% | 62.63% | 438.24% | -2,988.44% | -71.90% |
| Income Tax Expenses | 358.08% | 20.96% | -22.65% | -15.84% | -166.00% |
| Earnings from Continuing Operations | -54.88% | 61.37% | 425.03% | -4,781.76% | -63.82% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -54.88% | 61.37% | 425.03% | -4,781.76% | -63.82% |
| EBIT | -51.76% | 68.52% | 252.98% | -762.82% | -70.41% |
| EBITDA | -55.60% | 72.88% | 267.41% | -600.50% | -68.62% |
| EPS Basic | -37.44% | 65.81% | 334.89% | -3,282.54% | -18.41% |
| Normalized Basic EPS | -36.65% | 66.86% | 218.06% | -541.28% | -14.76% |
| EPS Diluted | -46.45% | 65.81% | 300.00% | -3,333.87% | -18.41% |
| Normalized Diluted EPS | -36.65% | 66.86% | 216.13% | -544.44% | -14.76% |
| Average Basic Shares Outstanding | 12.69% | 13.02% | 38.38% | 46.39% | 38.38% |
| Average Diluted Shares Outstanding | 12.69% | 13.02% | 40.70% | 45.08% | 38.38% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
